Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib Maintenance Therapy in Ph+ B-ALL Post-Transplant or CAR T
NCT07250087Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2026
- Primary completion
- Nov 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of asciminib in Acute lymphoblastic leukemia, Philadelphia chromosome positive (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
asciminib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT07250087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250087.